On 21 December 2017 the U.S. District Court for the Central District of California released its judgment in TCL Communications v Ericsson setting a Fair, Reasonable, and Non-Discriminatory (FRAND) rate for Ericsson’s Standard...more
The vexed question of how to enforce second medical use patents has dominated the headlines in the last half year. The case of Warner-Lambert v Actavis1 in the English High Court highlighted the serious difficulties...more
9/23/2015
/ Actavis Inc. ,
AstraZeneca ,
Claim Construction ,
EU ,
European Court of Justice (ECJ) ,
FRAND ,
Gilead Sciences ,
Hospira ,
Injunctions ,
IP License ,
IP Portfolio ,
Jurisdiction ,
Life Sciences ,
Patent Infringement ,
Patent Litigation ,
Patent Portfolios ,
Patents ,
Pharmaceutical Patents ,
Teva Pharmaceuticals ,
UK ,
UK Patents Act